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g.2012.0Abstract b-Thalassemia is considered the most common chronic hemolytic anemia in Egypt.
Patients with b-thalassemia whose anemia is not so severe as to necessitate regular transfusions
are said to have thalassemia intermedia. It is characterized by a signiﬁcant genetic and clinical het-
erogeneity. The clinical phenotype ranges between the severe, transfusion-dependent thalassemia
major and the asymptomatic carrier state. Thalassemia intermedia represents up to one-fourth of
b-thalassemia patients. It is essential to discuss the reasons for the remarkable heterogeneity and
natural history of thalassemia intermedia so that an effective method for the control and manage-
ment of thalassemia intermedia can be established. This review will outline the genetics of hemoglo-
bin biosynthesis as well as an overview on the pathogenesis, molecular basis, hematologic and
clinical features of thalassemia intermedia, in addition to management of complications affecting
patients with such disorder.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.Contents
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The thalassemia syndromes constitute the commonest of all
single gene disorders [1]. They are considered as the world’s
most widespread genetic diseases [2]. Beta thalassemia com-
prises a heterogenous group of hemoglobin disorders charac-
terized by a reduction or a complete absence of b-globin
gene expression [3] and is inherited as an autosomal recessive
disease [4]. The total annual incidence of symptomatic individ-
uals is estimated at 1 in 100,000 throughout the world [5].
In Egypt, homozygous beta (b) thalassemia was ﬁrst de-
scribed by Diwany in the year 1944. It is a signiﬁcant public
health problem in Egypt where over 1–5 million newborns
are expected to be affected with this disorder, and it is consid-
ered the most common chronic hemolytic anemia (85.1%) [6].
A high rate of carriers has been reported in Egypt ranging
from 4–5% [7] reaching up to 9–10% [8]. There is a high rate
of consanguineous marriage in Egypt which helps to accumu-
late deleterious genes in families, reaching 35.3% with an aver-
age inbreeding coefﬁcient of 0.019 which could be considered
high [9]. Hemoglobin is a tetramer with a molecular weight
of 64.5 kDa [10]. It consists of two a and two non-a globin
polypeptide chain, each of which has a single covalently bound
heme group [11]. Each of the four heme groups is made up of
an iron atom bound within a protoporphyrin IX ring [12].In
humans there are six known polypeptide chains designated a,
b, c, d, e, and f. The e, c and d chains are more similar to b
chains than to a chain and are designated b-like chains.
HbA (a2b2) is the major component of hemoglobin in normal
adults, usually comprising about 97% of the total hemoglobin.
The remainder is HbA2 (a2d2) which usually constitutes 2–3%
in normal individuals. HbF (a2c2), fetal hemoglobin, com-
prises the bulk of hemoglobin (50–85%) in human newborns,
but declines rapidly after birth, reaching concentrations of
10–15% by four months of age. Subsequently the decline is
slower and adult levels of less than 1% are reached by 3–
4 years. Hb Gower I (f2e2), Gower II (a2e2) and Portland
(f2c2) are embryonic hemoglobins synthesized in the yolk sac
before eight weeks of gestation [10]. The temporal switches
of globin synthesis are accompanied by changes in the major
site of erythropoiesis. Embryonic globin synthesis occurs in
the yolk sac from the third to eighth week of gestation [13]
with a decrease in f- and e-chain production together with a
compensating increase in a- and c-chain production. At this
stage of gestation, b-chain synthesis in reticulocytes accounts
for 4% of non-a chain synthesis and gradually increases there-
after, but about the ﬁfth week of gestation, the major site of
hematopoiesis begins to move from the yolk sac to the liver.
At around 8 weeks of gestation the fetal liver takes over, syn-
thesizing HbF plus a small amount of HbA. At 18 weeks ges-
tation the liver is progressively replaced by bone marrow as the
major site of red cell production, accompanied by a gradual
switch from HbF to HbA synthesis. Synthesis of the d chainalso continues after birth, but HbA2 (a2d2) never accounts
for more than about 2% of adult hemoglobin. Unfortunately,
the small amounts of d-globin (and therefore HbA2) and c-glo-
bin (and therefore HbF) that are found normally in adult
blood are insufﬁcient to compensate for the reduced amounts
of b-globin (and therefore HbA) that are found in diseases
such as b-thalassemia [10,11,13].
2. Genetics of hemoglobin biosynthesis
The genetic control of globin chain synthesis is primarily
achieved by two developmentally regulated gene clusters
(Fig. 1a–c) located on chromosome band 16p13.3 and
11p15.5 [for alpha (a)- and non-alpha(a)-gene cluster, respec-
tively] [14]. In humans there are eight different genetic loci that
code for the six types of globin chains. In addition there are at
least four pseudogenes that have sequences similar to other glo-
bin genes but are not expressed into globin proteins. In the b-
globin cluster, sequences around the gene appear to carry some
developmental speciﬁcity and the genes on the human b-globin
cluster are arranged in their temporal expression during devel-
opment [15]. The genes in each globin cluster are arranged
50 ﬁ 30 on the coding strands in the order of their developmen-
tal expression during embryonic, fetal and postnatal life [12].
The b-like globin genes spread over a region of approximately
60 kb. There are ﬁve functional genes: 50–e–Gc–Ac–wb–d–b-30.
The globin gene sequences comprise only 7 kb of the 60 kb of
DNA in the b-gene region, and the remaining 53 kb are ﬂank-
ing sequences that contain sequences with speciﬁc regulatory
roles. These include the locus control region, enhancer se-
quences and the promoter regions of the globin genes. The b-
locus control region (LCR-b) is found in a cluster of DNAse
I-hypersensitive sites 6–18 kb 50 to the e-globin gene. Erythroid
cells contain a variety of erythroid-speciﬁc transcription fac-
tors, the most important being GATA-1 and NF-E with bind-
ing sites both at the locus control regions and in the promoters
[10]. The b-globin promoter consists of a series of short func-
tional elements interacting with transcription factors that re-
strict expression of these genes to erythroid cells. One
important promoter sequence is the TATA box, a conserved
region rich in adenines and thymines, appears to be important
for determining the position of start of transcription, which is
approximately 50 base pairs upstream from the translation ini-
tiation site. A second conserved region, the CAT box (actually
CCAAT), is located further upstream [16–18]. Many mutations
in these regulatory elements have been identiﬁed in patients
with b-thalassemia. Enhancers are sequence elements that act
at a distance from a gene to stimulate transcription. They ap-
pear to be involved in establishing the tissue speciﬁcity or level
of expression of genes. Unlike promoters, enhancers are both
position and orientation independent and can be located either
50 or 30 of the transcription start site [17]. Mutations that dis-
rupt or delete either enhancer or LCR sequences interfere with
Figure 1 b-Globin gene cluster and a globin-gene cluster [10, 11 and 13].
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thalassemia demonstrated that the LCR is required for the
expression of all the genes in the b-globin cluster on chromo-
some 11 [19]. The LCR, along with associated DNA-binding
proteins, interacts with the genes of the locus to form a nuclear
compartment called the active chromatin hub, the compart-ment where b-globin gene expression takes place [14]. It is
involved in the sequential switching of gene from the
embryonically expressed e-globin gene to the d- and b-globin
genes in adults [20]. b-globin mutations have no prenatal con-
sequences because c-globin is the major b-like globin before
birth [13,16].
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Patients whose anemia is not so severe as to necessitate regular
transfusions are said to have thalassemia intermedia [11]. Thal-
assemia intermedia is characterized by a signiﬁcant genetic and
clinical heterogeneity. A wide spectrum of different genotypes
– homozygous, heterozygous and compound heterozygous –
have been thought to be responsible for thalassemia interme-
dia. The clinical phenotype ranges between the severe, transfu-
sion-dependent thalassemia major and the asymptomatic
carrier state [21]. It represents up to one-fourth of b-thalasse-
mia patients [22].4. Clinical features
 Some thalassemia intermedia patients are asymptomatic
until adult life and may present with moderate anemia
and do not require regular transfusions, whereas others
are symptomatic from as young as 2 years of age [23,24].
Red cell production in patients with b-thalassemia interme-
dia may be adequate to sustain hemoglobin of 6–7 g/dl [25]
without RBC transfusion [26].
 Main clinical features that may be present in patients with
thalassemia intermedia are hypertrophy of erythroid mar-
row with medullary and extramedullary hematopoiesis with
its complications (osteoporosis, masses of erythropoietic
tissue that primarily affect the spleen, liver, lymph nodes,
chest, spine with bone deformities and typical facial
changes) and gallstones[5]. Pathologic fractures and skeletal
abnormalities occur due to massive expansion of erythroid
bone marrow activity and hepatosplenomegaly due to
hemolysis or extramedullary hematopoiesis [26].
 Although chronically anemic [11,27] the need for transfu-
sion support might be eliminated or delayed thereby mini-
mizing iron overload at the expense of severe anemia,
with consequent cardiomegaly, splenic enlargement, osteo-
porosis and bony deformities [25]. Transfusion may become
necessary with advancing age, during infection and preg-
nancy, and when hypersplenism develops [28].
 Iron overload in non-transfused patients is due to aug-
mented gastrointestinal absorption and involves mainly
the liver [28]. The hepatic peptide hepcidin, normally regu-
lated by marrow activity and by iron load, is disproportion-
ately low in individuals with thalassemia, allowing iron to
be absorbed from the gut even in the presence of severe
overload [29]. Iron-induced peroxidative injury to the phos-
pholipids of lysosomes and mitochondria, produced by free
hydroxyl radicals, is believed to be the most important
pathogenetic factor for tissue damage. The estimated
amount of iron that subjects with thalassemia intermedia
absorbed on a standard diet is 3–10 times more than is nor-
mal. By the third or fourth decade, the iron load may be
similar in magnitude to that of transfusion-dependent thal-
assemic patients in their teens [11].
 Although individuals with thalassemia intermedia are at
risk of iron overload, hypogonadism, hypothyroidism and
diabetes are not common [30].
 Although patients with thalassemia intermedia (TI) are
capable of surviving without regular blood transfusion,
growth and development are retarded [5]. Pubescence takes place normally, and fertility is preserved
[31]. Women may have successful spontaneous pregnancies.
However, if blood transfusions are necessary during preg-
nancy, those never or minimally transfused are at risk of
developing hemolytic alloantibodies and erythrocyte auto-
antibodies. Intrauterine growth retardation, despite a regu-
lar transfusion regimen, has been reported due to hypoxia
[32]. Splenomegaly can interfere with the enlargement of
uterus and can be complicated by hypersplenism [33].
 Pallor, intermittent icterus, and facial bony changes similar
to those of thalassemia major are observed regularly [23].
 Survival into adulthood is the rule [27].
5. Complications affecting patients with thalassemia intermedia
 Pulmonary hypertension and thromboembolic events
[23,28]. Hemolysis per se has been linked to the develop-
ment of a hypercoagulable state and pulmonary hyperten-
sion (PHT). The pathogenesis may include: activation of
platelets, endothelial cells and monocytes [34] with
increased both thromboxane, and endothelin, decreased
prostacycline [33] along with dysfunction of the coagulation
system. These have been associated with thromboembolic
phenomenon, especially in splenectomised thalassemia
intermedia patients. Moreover, hemolysis carries a role in
the dysregulation of nitric oxide (NO) homeostasis which
is correlated with PHT and probably thrombotic phenom-
ena [34]. Such events include deep vein thrombosis, portal
vein thrombosis, stroke and pulmonary embolism [35].
 In both patients with beta thalassemia major and beta thal-
assemia intermedia, total cholesterol and LDL-cholesterol
are decreased. The mechanisms that may account for these
ﬁndings are increased erythropoiesis and cholesterol con-
sumption in beta thalassemia intermedia, and iron overload
and oxidative stress in beta thalassemia major [36].
 Cardiac disease in thalassemia intermedia is determined by
two main factors. One is the high output state that results
from chronic tissue hypoxia and from hypoxia-induced
compensatory reactions. The other is the vascular involve-
ment that leads to an increased pulmonary vascular resis-
tance and an increased systemic vascular stiffness.
Valvular abnormalities and iron overload also contribute
to a less extent. Right heart involvement with age-related
pulmonary hypertension followed by congestive heart fail-
ure dominates the clinical picture. Although the left heart
is also affected, systolic left ventricular function is usually
preserved but this may also be decompensated under condi-
tions characterized by excessive cardiac work load [34].
Patients with thalassemia intermedia who do not usually
have severe hemosiderosis are less prone to cardiac prob-
lems [37].
 Pseudoxanthoma elasticum, a diffuse connective tissue dis-
order with vascular manifestation: caused by degeneration
of the elastic lamina of the arterial wall and calcium depo-
sition, has been described in such patients [38]. The patho-
physiology has been attributed to iron-induced oxidative
damage. Its progression is complicated by thrombotic and
hemorrhagic events similar to those of the inherited form
[39].
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racic and sometime accompanied by hemothorax. It is due
to the chronic anemia and the associated hypoxia with the
frequent extramedullary erythropoiesis [40]. Spinal cord
compression may cause paraparesis and cauda equina syn-
drome [41].
 Leg ulcers over the medial malleolus are common in thalas-
semia intermedia. Their pathogenesis has been related to:
hypoxia caused by chronic anemia, abnormal rheology of
the thalassemic red cells, venous stasis and high HbF con-
centration [33].
 Hepatocellular carcinoma represents a frequent complica-
tion in patients with liver cirrhosis either secondary to
genetic hemochromatosis or to chronic viral hepatitis. As
a consequence of the numerous risk factors present in thal-
assemia patients, the development of the tumor is to be
expected [42].
 The primary cause of premature death is myocardial hemo-
siderosis [11].
6. Management
Currently there are no clear guidelines for managing patients
with thalassemia intermedia [43]. There are a number of op-
tions currently available for managing patients with thalasse-
mia intermedia including:
 Transfusion therapy: increasing evidence is delineating the
beneﬁt of transfusion therapy in decreasing the incidence
of complications as pulmonary hypertension and thrombo-
embolic events. Thus although the common practice was to
initiate transfusion when complications ensue, it may be
worthwhile to start transfusion therapy earlier as a preven-
tive approach which will also help alleviate the increased
risk of alloimmunization with delayed initiation of transfu-
sion. Although earlier introduction of blood transfusions
will increase the rate of iron accumulation, effective meth-
ods of iron chelation are now available [44,34]. Transfusion
becomes necessary when the sense of well being of the
patient decreases to a level inadequate to the activities of
a normal life. Problems usually develop, in patients used
to chronic hypoxia, for levels of Hb below 70 g/l. The
patient’s general condition must be considered in terms of
regular growth, growth velocity, bone age, bone deformi-
ties, size of the spleen, periods of rapid growth and preg-
nancy. Sometimes transfusion becomes necessary during
infection-induced aplastic crises. Heart disease is also an
indication to transfusion therapy. When the decision to
transfuse is made, the transfusion regimen should be similar
to the one generally adopted for thalassemia major [34].
 Splenectomy: The current indications for splenectomy in TI
include growth retardation, leukopenia, thrombocytopenia,
increased transfusion demand and symptomatic splenomeg-
aly [45]. Splenectomy, however, can contribute to an
increased susceptibility to thromboembolic events and pul-
monary hypertension in TI [23].The presence of a chronic
hypercoagulable state could be due to the procoagulant
effect of the anionic phospholipids exposed on the surface
of the damaged circulating red blood cells [46]. Overwhelm-
ing postsplenectomy sepsis is an abrupt event that can befatal. The most frequent bacteria are Streptococcus pneumo-
niae, Hemophilus inﬂuenzae, Neisseria meningitidis, Klebsi-
ella, Escherichia coli and Staphylococcus aureus [34]. Iron-
loaded macrophages lose the ability to kill intracellular
pathogens via the interferon-c-mediated pathways. Some
of this loss of ability is related to the reduced formation
of nitric oxide in the presence of iron [47]. Splenectomy usu-
ally allows discontinuation of transfusion in the majority of
the patients. However, it does not usually modify the high
output state and the increased pulmonary artery pressure
that often characterizes thalassemia intermedia [48]. If
gallstones are present, cholecystectomy should also be per-
formed at the time of splenectomy [34]. Partial splenectomy
and partial dearterialization of the spleen have an immedi-
ate beneﬁcial effect, but are not long-lasting [49].
 Iron chelation therapy: Iron chelation, when begun after age
of 10 years may not prevent the development of overt
cardiac disease [50]. A direct assessment of liver iron
concentration is recommended, either by biopsy or by a
non-invasive method such as R2 MRI. Chelation therapy
should generally be initiated if liver iron concentration
exceeds 7 mg/g dry weight of liver tissue. Threshold serum
ferritin values of 400–500 ng/ml could be considered as an
indicator for initiation of iron chelation therapy [51]. The
orally active chelators seem to be more efﬁcient in gaining
access to the chelatable iron pools of cardiomyocytes, bind-
ing labile iron, and attenuating reactive oxygen species
formation [52].
 Modulation of fetal hemoglobin production: It has been sug-
gested that increasing levels of hemoglobin F (a2c2) by
pharmaceutical agents could be of beneﬁt in patients with
b -thalassemia intermedia because of an improvement in
the balance off globin synthesis [53]. Hydroxycarbamide,
also known as hydroxyurea is capable of inducing HbF syn-
thesis and stimulating c-globin production. It may have a
more general role in augmenting globin synthesis, including
b-globin in some thalassemia intermedia patients who
maintain the capacity to express normal b-globin chains
[25]. Both hydroxyurea and butyrate derivatives have
shown only modest increases in hemoglobin [54]. Some
patients with b-thalassemia intermedia, who are not trans-
fusion dependent, may respond to hydroxyurea treatment,
albeit transiently [55] by increasing their packed cell vol-
umes [56]. Hydroxycarbamide has been administered to
thalassemia patients according to many different regimens,
alone or in combination with other drugs [33]. A signiﬁcant
decrease in the need for blood transfusions was observed in
many patients; the need was completely obviated in some
patients [57]. a-deletions, the XmnI polymorphism [58]
and Hb E/b-thalassemia [59] may be predictive of a good
response to hydroxycarbamide. The improved sense of
well-being, almost universally reported, may reﬂect the sig-
niﬁcant decrease of ineffective erythropoiesis [60]. Trials of
recombinant human erythropoietin (rHuEPO) for the treat-
ment of thalassemia in humans showed a signiﬁcant, dose-
dependent increase in thalassemic erythropoiesis, without
an increase in HbF, mean corpuscular volume and mean
hemoglobin content, and without a change in the a/non-a
ratio has been observed, mainly in splenectomized patients
with thalassemia intermedia [61]. Combination therapy
with erythropoietin and hydroxyurea in thalassemia
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apy alone with respect to HbF augmentation and an
increased packed cell volume [62,56]. Haemin, the ferric
chloride salt of heme, when combined with erythropoietin,
preferentially increased the production of HbF in human
erythroid cells [60].
 Antioxidants: Oxidative damage may be generated by the
presence on the cells of free globin chains and labile plasma
iron (LPI), a chelatable component of non-transferrin-
bound iron [63] and can be reduced by treatment with iron
chelating agents. Reactive oxygen species play an important
role also in the oxidative state of platelets potentially favor-
ing thromboembolism. The chronic stress on neutrophils
can reduce their antibacterial capacity and their respiratory
burst response [64]. Combined use of a lipid antioxidant
(vitamin E) with a protein antioxidant (N-acetylcysteine)
and iron chelators could be more effective than the admin-
istration of a single antioxidant [65].
 Folic acid supplementation: Folic acid deﬁciency is common
in TI and occurs due to poor absorption, low dietary intake,
or, most signiﬁcantly, an increased demand for folic acid
from active bone marrow with increased erythropoiesis.
This is a particular concern in pregnancy since deﬁciency
can cause neural tube defects, such as spina biﬁda, in the
growing fetus [33,34]. Daily supplementation with 1 mg of
folic acid is advised for patients with thalassemia intermedia
[66].
 Zinc supplements: Zinc supplementation may become neces-
sary during intense chelation [33].
 Hematopoietic stem cell transplantation: Hematopoietic
stem cell transplantation (HSCT) is an established treat-
ment for beta-thalassemia major [34], but it has rarely been
used in patients with thalassemia intermedia [33]. The deci-
sion as to which patients are eligible for transplantation is
complex and is related to both the quality of life and
expected survival-time of the transplanted patient, when
compared with supportive care only [34].
 Molecular therapies and future perspectives: The transfer of
a globin gene in autologous haematopoietic stem cells poses
challenges in terms of controlling transgene expression,
which ideally should be erythroid-speciﬁc, differentiation-
and stage-restricted, position independent and sustained
over time [67]. Considerable progress has now been made
using lentiviral vectors [68]. Globin gene transfer by homol-
ogous recombination in ex vivo embryonic stem cells is a
possibility for the hemoglobinopathies [69]. Therapeutic
antisense mRNA using antisense oligonucleotides targeted
at aberrant splice sites can restore correct splicing in ery-
throleukaemic cell lines. These studies have implications
for the treatment of HbE/b-thalassaemia [70]. a-hemoglobin
stabilizing protein (AHSP) binds free a-globin chains, limit-
ing the oxidative effects of a-Hb and prevents its precipita-
tion. In humans, it is directly regulated by GATA-1[33].
 Treatment of complications
– The development of pulmonary hypertension could be
prevented by starting transfusion and chelation therapy
early in life for patients with thalassemia intermedia [3-
3]. Several therapies have been available for the treat-
ment of pulmonary hypertension including oxygen
therapy, diuretics, digoxin, anticoagulants and calcium
channel blockers. In addition, Prostacyclin analogs, en-
dothelin receptor antagonists and phosphodiesterase 5inhibitors have been introduced for the treatment of pul-
monary hypertension [71,72]. Treatment of extramedul-
lary erythropoietic masses includes hypertransfusion
[41], radiotherapy, hydroxycarbamide [73] and surgery
in selected cases [74].
– Leg ulcers: The treatment is difﬁcult and includes
pressure dressing, skin grafting, blood transfusion, hy-
droxycarbamide, arginine butyrate, granulocyte col-
ony-stimulating factor, rHuEPO, platelet growth factor
and local hyperbaric oxygen chamber [75].
– Fractures due to minor traumas may suggest the need for
transfusion [76]. 25-OH vitamin D deﬁciency has been
reported [77]. Vitamin D may be given in a dose of 70-
0–800 IU [78] and calcium should be given at 1200–150-
0 mg/day [79]. Additional therapy may be necessary
including biphosphonates, potent inhibitors of osteoclast
activation [80]. However, care should be taken because
several cases of jaw necrosis have been described [81].
– Prevention and therapy of thromboembolic events [5].
Ischemic strokes have been described in combination
with cardiac valvular lesions – a consequence of the
elastic tissue defect and/or atrial ﬁbrillations on a back-
ground of hypercoagulability. At the same time, throm-
bosis may be a silent or subclinical process [82]. Early
transfusion therapy, combined with iron chelation,
may prevent heart damage by ameliorating factors that
cause cardiac deterioration, such as high output state,
hemolysis and hypercoagulability [83]. Blood transfu-
sion might reduce the thrombotic risk by diluting the
procoagulant thalassemic red cells. Platelet anti-aggrega-
tion agents and low molecular weight heparin followed
by long-term oral anticoagulants in patients with a
history of thrombosis seem reasonable choices [33].
7. Molecular basis of b-thalassemia intermedia
Beta-thalassemias are caused by point mutations or, more
rarely, deletions in the beta globin gene on chromosome 11,
leading to reduced (beta+) or absent (beta0) synthesis of the
beta chains of hemoglobin (Hb). Transmission is autosomal
recessive; however, dominant mutations have also been re-
ported [5]. More than 200 mutations have been reported that
result in beta-thalassemia in the b-thalassemia globin gene
[10,84], together with a much smaller number of gene dele-
tions ranging from 25 bp to 67 kb [85]. Comparison between
the prevalence of b-thalassemia mutations in thalassemia ma-
jor and thalassemia intermedia in the Mediterranean region is
shown in Table 1. The clinical severity of b-thalassemia
depends mainly on the degree of b chain deﬁciency [86]. The
mutations either affect globin gene transcription, RNA pro-
cessing or translation, RNA cleavage and polyadenylation,
or result in a highly unstable globin chain. Frameshift and
nonsense codon mutations have been observed in all three
exons, and RNA processing mutations have been found in
both introns and the four splice junctions. Transcription
mutations are all relatively mild and are commonly observed
in b-thalassemia intermedia; they are single nucleotide substi-
tutions in the TATA box at 30 from the transcription
start site and in the ACACCO distal promoter region at
90 [10].
Table 1 Comparison between prevalence of b-thalassemia
mutations in thalassemia major and thalassemia intermedia in
the Mediterranean region [117,34].
Mutation Thalassemia intermedia
N (%)
Thalassemia major
N (%)
cd39 C->T 72(24) 136(53.5)
IVSI-110 G->T 52(17) 58(23)
IVSI-6 T->C 94(31.5) 16(6.3)
IVSI-1 G->A 8(2.7) 19(7.4)
IVSII-1G->A 14(4.7) 10(3.9)
IVSII-745 C->G 11(3.7) 9(3.5)
101 C->T 10(3.3) –
cd6-A 10(3.3) 3(1.2)
87 C->G 8(2.7) –
db Siciliana 13(4.3) –
Lepore Boston 2(0.7) –
IVSI-5 G->A – 1(0.4)
IVSI-5 G->C 1(0.3) –
IVSII-844 G->C 1(0.3) –
IVSI-2 T->A 1(0.3) –
cd 44-C – 1(0.4)
cd 8-AA 1(0.3) 1(0.4)
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interplay of several genetic factors. It is essential to determine
the reasons (or genetic modiﬁers) for the remarkable pheno-
typic heterogeneity and natural history of these disorders so
that the most cost-effective methods for their control and man-
agement can be established [87].
Modiﬁer genes are deﬁned as inherited genetic variation
that leads to a qualitative or quantitative difference in disease
phenotype. This has made the prediction of the phenotype
based upon the genotype more difﬁcult. Beta-thalassemia phe-
notype is modiﬁed by co-existent other genetic alterations.
Beta-thalassemia has been found in association with other
hemoglobins: Hb D, Hb G, Hb J-Baltimore and Hb KO¨ln.
Hemolytic anemia, if present, is of mild to moderate severity.
In combination with Hb Crete, a b-chain variant with high
oxygen afﬁnity, b0- and db-thalassemia produce an unusual
clinical picture of an overcompensated hemolytic state, with
erythrocytosis, splenomegaly, abnormal red cell morphology,
and marked erythroid hyperplasia [11].
Genetic modiﬁers of b-thalassemia have been classiﬁed
into:
(1) Primary modiﬁers, which describe the different b alleles
of varying severity. They primarily affect the clinical presenta-
tion including inheritance of a mild b-thalassemia mutation,
alpha gene changes, XmnI polymorphism and hereditary
persistence of fetal hemoglobin (HPFH) variants [88,89]. In
general, any factor able to reduce the globin chain imbalance
results in a milder form of thalassemia including the presence
of silent b-thalassemia allele, associated with a high residual
b-globin production [90]. It is not possible to consistently
predict phenotype from a and b genotypes alone, due to the
inﬂuence of modulating factors [91,92]. The syndrome of inter-
mediate severity between thalassemia major and thalassemia
minor may be produced by homozygous state of some b-thal-
assemia alleles [88]. A few mutations have been described, in
the promoter or in the 50 untranslated regions, of the b-globingene leading to a slight decrease of b-globin chain synthesis
[85]. Carriers of the silent mutations show normal or slightly
decreased hematologic parameters and a normal or slightly
elevated Hb A2 level; the co-inheritance of another b-thalasse-
mia mutation in trans gives rise to a thalassemia intermedia
phenotype. Silent thalassemia mutations are most often identi-
ﬁed among thalassemia intermedia patients who have one
parent with a normal phenotype [93–95]. The doubly heterozy-
gous state for the b0- and (db)0-genes has been described in
Greek, Italian, Oriental and black patients with thalassemia
intermedia [11]. Hemoglobin Lepore in association with either
the b0- the b+-gene also produces a thalassemia of intermedi-
ate severity [2]. The homozygous state for the (db)0-thalasse-
mia gene regularly produces thalassemia intermedia [96]. Hb
A and Hb A2 are absent owing to deletion of the b- and
d-structural genes. The relatively benign nature of homozygous
db-thalassemia relates to greater preservation of c-chain syn-
thesis than is the case in the usual forms of homozygous b-thal-
assemia. Individuals with a high c/a-ratio have a smaller free
a-chain pool and the clinical syndrome of thalassemia interme-
dia rather than thalassemia major [11].
(2) Secondary modiﬁers, which describe the co-inheritance
a-thalassemias or genetic determinants which increase the level
of Hb F production, both of which reduce the degree of glo-
bin-chain imbalance. The secondary modiﬁers affect the sever-
ity of jaundice, bone disease, cardiac and thrombotic
complications [88]. The interaction of a- and b-thalassemias
gives rise to a chronic hemolytic anemia of only intermediate
severity. Coinheritance of a-thalassemia in homozygotes or
in double heterozygotes for severe and mild b-thalassemia
mutations have repeatedly been found in long-living patients
with thalassemia intermedia [97]. Alpha-hemoglobin-stabiliz-
ing protein (AHSP) is an erythroid-speciﬁc protein that acts
as a molecular chaperone for the free a chains of hemoglobin.
Evidence strongly suggests that AHSP participates in hemo-
globin synthesis and may act to neutralize the cytotoxic effects
of excess free alpha-globin subunits that accumulate both in
normal and beta-thalassemic erythroid precursor cells. As
such, AHSP seems to be essential for normal erythropoiesis,
and impaired upregulation of AHSP may lead to premature
erythroid cell death, resulting in ineffective erythropoiesis. Re-
duced AHSP mRNA expression has been associated with clin-
ical variability in some cases of b-thalassemia [98]. Galanello
et al. [99] provided the ﬁrst evidence that AHSP could modu-
late b-thalassemia. They reported the association of reduced
AHSPmRNA expression and a more severe phenotype among
individuals with identical b-thalassemia genotypes in two unre-
lated Sardinian families. Several different genotypes have been
deﬁned: homozygous a0-thalassemia with heterozygous b0- or
b+-thalassemia, heterozygous a+-thalassemia with heterozy-
gous b-thalassemia, Hb H disease with heterozygous b-thalas-
semia, and heterozygous a0-thalassemia with homozygous
b-thalassemia [100–102]. The combination of the triple a-glo-
bin gene and the heterozygous state for b0-thalassemia also
is characterized clinically by mild thalassemia intermedia [6].
Coinheritance of a-thalassemia with heterozygous b-thalasse-
mia does not usually result in reduction of the increased Hb
A2 level typical of b-thalassemia. On the contrary, different
d-globin gene defects in cis and in trans to high Hb A2 b-thal-
assemia mutations constantly reduce the Hb A2 level [103,104].
Increased Hb F levels have been associated with certain
252 R.M. Shawky, T.M. Kamalb-globin gene promoter mutations such as those in proximal
CACCC box [105]. The striking inverse correlation between
the Hb F and Hb A2 levels is interesting, as it could reﬂect
competition between adult and fetal globin genes for cis-acting
regulatory elements such as the LCR [86]. Sequence variations
located in the LCR 50 HS-2 [106], the Ac IVS-II [107] and the 50
ﬂanking region of the b-globin gene [108] have also been impli-
cated in the regulation of Hb F expression, mainly in patients
with sickle cell anemia (SS) and b-thalassemia. Analysis of the
possible sequence variations within the b-globin gene cluster
that could have an effect on the c chain production concerned
ﬁrst the LCR 50 HS-4, HS-3 and HS-2 regulatory segments be-
cause of their role in conferring high level erythroid-speciﬁc
expression on the b-like globin genes, and because of the ﬁnd-
ing of gene and developmental stage speciﬁcity for the HS-4
and HS-3 elements [109]. Additional studies included the c-glo-
bin gene promoters, the 50 ﬂanking sequences and the IVS-II,
since these regions also contain sequences involved in modulat-
ing the globin gene expression [110]. The 50 ﬂanking regions of
the b-globin genes were investigated because of the presence of
polymorphic AT repeats from position 540 which have been
implicated in regulation of globin gene expression through dif-
ferential binding of the negative transacting factor BP-1 [111].
An X-linked determinant has also been associated with ele-
vated Hb F levels and F-cell production in normal adults
and SS patients [112].
The inheritance of a speciﬁc arrangement of restriction
fragment length polymorphism (b RFLP haplotype +
++ 50) associated with a high Hb F determinant, and
the inheritance of a mild b-thalassemia gene are the major
factors that modify the severity of the disease in Asian Indi-
ans. The inheritance of a b chromosome with the Xmn I-c
(+) haplotype is clearly associated with a milder phenotype.
However, a single copy of this haplotype-associated determi-
nant may not be enough to affect a sufﬁcient increase in Hb
F to modify b0-thalassemia. In contrast, patients who were
Xmn I-c (±) all had a mild disease [89]. Homozygote of
the XmnI site, +/+, was found to have a strong linkage with
high Hb F levels and high hemoglobin production in two pa-
tients who had mild clinical symptoms. However, some pa-
tients who had XmnI site / also had mild clinical
symptoms because the XmnI- was found to be associated with
beta+-thalassemia mutation [113,57]. Two common underly-
ing mechanisms include co-inheritance of alpha globin gene
deletions in homozygous thalassemia intermedia and presence
of XmnI polymorphism. The newly described mechanisms in-
clude unstable hemoglobin disorders and somatic deletions in
beta-globin gene [114]. Papachatzopoulou et al. [115] estab-
lished that (i) The combination of T haplotype of the Ac–d-
globin intergenic region, the motif (TA)9N10 in HS2 site of
locus control region (LCR), and TAG pre-Gc haplotype is
sufﬁcient but not necessary for high Hb F [116]. (ii) The ge-
netic determinant(s) for high Hb F involves an element asso-
ciated with this combination and must be present in the
speciﬁc R haplotype occurring in b-thalassemia intermedia.
(iii) The genetic determinants for high Hb F does not involve
the abolition of intergenic transcription in the Ac–d-globin
intergenic region.
(3) Tertiary determinants, which are applied to modiﬁers
that, although not involved in hemoglobin synthesis, cause
variation in the degree of severity of many complications of
b-thalassemia [16].7.1. Pathophysiology and hematologic features of the main types
of globin gene disordersDecreased b-globin production causes hypochromic, micro-
cytic anemia and imbalance in globin synthesis leading to pre-
cipitation of a chains. The excess a chains are insoluble which
in turn leads to damage of the red cell membrane and ineffec-
tive erythropoiesis. Because d gene is intact, HbA2 production
continues. Elevation of HbA2 level is unique to b-thalassemia
heterozygotes. The level of Hb F is also increased, not because
of a reactivation of the c-globin gene expression that was
switched off at birth, but because of selective survival and per-
haps increased production of the minor population of adult
red blood cells that contain Hb F [13]. The severity of thalas-
semia intermedia depends on the degree of imbalance between
alpha and non-alpha chains as well as other genetic and envi-
ronmental factors that modify the natural history of the dis-
ease. By deﬁnition, the patients spontaneously maintain
hemoglobin at or above 7 g/dL, sometimes at the price of in-
tense hyperplasia of the bone marrow that is in turn responsi-
ble for bone deformities, osteoporosis, and extramedullary
erythropoietic masses that often characterize thalassemia inter-
media [54].
Peripheral blood erythrocytes show signiﬁcant anisocytosis,
hypochromia, target cells, basophilic stippling, and nucleated
forms. Bone marrow hyperplasia is prominent with inclusion
of denatured a-chains can be demonstrated in late norombo-
blasts. The hemoglobin electrophoretic pattern is highly vari-
able reﬂecting the heterogeneity of genotypes [117]. Db-
thalassemia is a mild disorder and one of the types of thalasse-
mia intermedia. Homozygotes have 100% HbF and lack HbA
and HbA2. The mild anemia and hemolysis are due to increased
c-chain synthesis, which makes imbalance between synthesis of
a chains and non-a chains less than that seen in other b-tha-
lassemias [85]. They are classiﬁed into two groups, the (db)0-
thalassemia, in which the HbF is composed of both Gc and
Ac chains, and the (Acdb)0-thalassemias, in which the HbF con-
tains only Gc chains [10]. In the homozygous state, the hemato-
logic features of Hb Lepore show thalassemia major/
intermedia with HbF about 80% and Hb Lepore 20%. The
HbE/b-thalassemia exhibits a varied clinical expression ranging
from severe transfusion dependence to relatively mild thalasse-
mia intermedia [92]. The severest conditions are found in indi-
viduals with b0-thalassemia who usually have about 50–70%
HbF, the remainder being HbE. Compound heterozygotes
for HbE and b+-thalassemia have a milder disorder [10]. Coin-
heritance of alpha-thalassemia with beta0-thalassemia/Hb E
produces a milder clinical phenotype in contrast to an interac-
tion of alpha-globin gene triplication in severe thalassemia
[118]. Infants heterozygous for the rare condition of ecdb-thal-
assemia are born with a hemolytic, hypochromic anemia and
microcytosis. The condition improves at 3–6 months after birth
to become similar to heterozygous b-thalassemia, with normal
HbA2 level [85].References
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